Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid in hyperlipidemia not adequately controlled by statins
NCT06780410Phase 3Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary hyperlipidemia comparing Bempedoic acid with Placebo (2 arms). Primary endpoint: Percentage change from baseline in LDL-C levels at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
bempedoic acid
03
Conditions
primary hyperlipidemia
Beyond the preview
Go deeper on NCT06780410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780410.